Open AccessDrug Development from Peptide-derived Marine Natural Products
Author(s) -
Linda Sukmarini
Publication year - 2021
Publication title -
iop conference series. materials science and engineering
Language(s) - English
Resource type - Journals
eISSN - 1757-899X
pISSN - 1757-8981
DOI - 10.1088/1757-899x/1011/1/012063
Subject(s) - drug development , peptide , drug , ribosomal rna , computational biology , drug discovery , chemistry , biology , combinatorial chemistry , biochemistry , pharmacology , gene
Marine natural products (MNPs) provide an ample source of pharmacologically bioactive compounds with great chemical diversity and complexity. Peptide-derived MNPs are a class of compounds with diverse and interesting biological properties, such as antiinfective, anticancer, cytotoxic, and antiallodynic. Their biosynthetic production machinery from the ribosomal origin or non-ribosomal origin and the hybrid with other compounds confer these compounds remarkable diversity in terms of structural complexity as well as biological activity. The interest in these peptide compounds is their potential to produce valuable therapeutics and pharmaceuticals. Some of these peptides or their derivatives have reached the pharmaceutical market, while some are currently under clinical trials for developing new drugs. This review focuses on marine peptide-based compounds in advanced drug development for clinical use or pharmaceutical applications. The drug development process and clinical status of ribosomal peptides, non-ribosomal peptides and their hybrids, or the derivatives, are hereby described.